Abstract | PURPOSE: METHODS: We conducted a systematic review and meta-analysis according to PRISMA guidelines. We queried PubMed and Web of Science databases on 1 July 2021. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to Cochrane's Q test and I2 statistic, respectively. RESULTS: Six retrospective studies (n = 50,220 patients) were selected after considering inclusion and exclusion criteria for qualitative evidence synthesis. Four retrospective studies were included to assess the SARS-CoV-2 infection risk in PCa patients under ADT vs. no ADT and the summarized risk ratio (RR) was 0.8 (95% confidence intervals (CI) 0.44-1.47). Five retrospective studies were included to assess the severity of coronavirus disease 2019 (COVID-19) in PCa patients under ADT versus no ADT and the summarized RR was 1.23 (95% CI 0.9-1.68). CONCLUSION:
|
Authors | Reza Sari Motlagh, Mohammad Abufaraj, Pierre I Karakiewicz, Pawel Rajwa, Keiichiro Mori, Dong-Ho Mun, Shahrokh F Shariat |
Journal | World journal of urology
(World J Urol)
Vol. 40
Issue 4
Pg. 907-914
(Apr 2022)
ISSN: 1433-8726 [Electronic] Germany |
PMID | 34477955
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Copyright | © 2021. The Author(s). |
Chemical References |
- Androgen Antagonists
- Androgens
|
Topics |
- Androgen Antagonists
(therapeutic use)
- Androgens
- COVID-19
- Humans
- Male
- Pandemics
- Prostatic Neoplasms
(drug therapy, epidemiology)
- Retrospective Studies
- Risk Factors
- SARS-CoV-2
- Severity of Illness Index
|